Antares pharma announces fda acceptance of ind application for atrs-1902 for adrenal crisis rescue

Ewing, n.j., july 22, 2021 (globe newswire) -- antares pharma, inc. (nasdaq: atrs) (“the company”), a specialty pharmaceutical company, today announced that the u.s. food and drug administration (fda) has accepted the investigational new drug application (ind) for atrs-1902 for adrenal crisis rescue. the active ind enables antares to initiate a phase 1 clinical study for atrs-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel proprietary auto-injector platform to deliver hydrocortisone.
ATRS Ratings Summary
ATRS Quant Ranking